DOCSLIB.ORG

Lethal Effects of Ivermectin on Anophezes Quadnimaculatus

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lethal Effects of Ivermectin on Anophezes Quadnimaculatus 278 JoURNALoF THE AupRrcau Moseurro CoNtnor, AssocretroN Vor,.8,No.3 LETHAL EFFECTS OF IVERMECTIN ON ANOPHEZES QUADNIMACULATUS J. W. JONES, M. V. MEISCH, C. L. MEEK1 lNo W. S. BIVIN' Department of Entomology,Uniuersity of Arknnsas,Fayetteuille, AR 72701 ABSTRACT. Female Anophelesquadrimorulatus adults were blood fed on 15 mixed breed dogs 4 h after the dogswere given oral dosagesof ivermectin. Dogs were divided into 5 treatment groups of 3 dogs each, at 10, 500, 1,000, 2,500 ptg/kg, and.untreated. Additionally, An. quadrimaculatus werc fed on lambskin-membranescontaining blood drawn from one dog in each treatment group. Mosquitoes wele allowed to feed on the dogs or the lambskin-membranesand were observedfor death at 24 and 48 h post-feeding.Greater than g0% mortality was recordedin all ivermectin treatment groups except at the 24 h post-feedingperiod with the l\pe/ke dog dose blood fed through the lambskin-membrane (65.4Vo mortality). The highest 2 dosagesproduced 100% mosquito mortality at 48 h post-feedingfrom either a dog or the in uitro systemusing a lambskin-membrane. INTRODUCTION MATERIALS AND METIIODS Avermectins have a wide range of activity Adults of An. quadrirnaculatuswere obtained against a large number of helminths and arthro- from resting stations on the University of Ar- pods. Many publications describe the effect of kansas Rice Researchand Extension Center avermectins on helminths and arthropods par- approximately 13 km east of Stuttgart, AR (Ar- asitic on mammals, but few studies report the kansas County). Female mosquitoeswere man- effect of these compoundson mosquitoes. ually separatedfrom malesby chilling collection Pampiglioneet al. (1985)reported 100% mor- tubes in a freezer for 40 sec and then placing tality in Arwpheles stephensi Liston 36 h after them on a chill table. Aliquots of 40 females feeding on mice given 2.8 mg/kg of ivermectin, weretransferred by mouth aspirator to each236- a semisyntheticavermectin. When Aedesaegypti ml cardboard container (Fonda Group Inc., (Linn.) and.Culex quinquefasciatusSay were fed Union, NJ).3 Each container was subsequently on mice given 28 mg/kg of ivermectin they ex- covered with nylon mesh screening. Seventy hibited abort 50% mortality within 72 h of feed- containers of mosquitoeswere placed in an in- ing. The LD56 for Cx. quinquefasciotusfed on sulatedchest for ground transportation to Baton ivermectin-treated mice was 82 mg/kg. Focks et Rouge,LA. Moistened paper toweling was added al. (1991) examined the effects of ivermectin on to the chest to sustain a high humidity level for the reproductive rate of.Ae. aegypti. After Ae. mosquito survival during transportation. aegyptifemales were fed on rabbits injected with Fifteen mixed breed dogs,housed at the Lou- ivermectin at 10 mg/kg, the mosquitoes exhib- isiana State University School of Veterinary ited reduced survival and egg production when Medicine, were divided into 5 groups of 3 dogs compared with females fed on control rabbits. with one group acting as a control (untreated). Ivermectin levels of 3.4 and 4.3 ng/ml in human Dogswere approximately 1 year old and weighed blood caused 50% of Ae. aegypti and Aedes aL- 19.0+ 3.6 kg. Ivermectinawas diluted with For- bopictus (Skuse) eggsto be infertile (Tesh and mulation Bu and was administered orally with a Guzman 1990).They reported that the LDsosfor 3 cc syringe atl0 pg/kg (: the prophylactic dog Ae. aegypti,Ae. albopictusand Cr. quinquefascia- heartworm dosage),500 pg/kg, J",000pg/kg and tus fed ivermectin in human blood were 126,208 2,500pg/kg. The control dogswere given 3 cc of and 698 ng/ml, respectively. Formulation B. Four hours after administering We evaluatedthe effects of canine blood con- ivermectin, the dogs were immobilized using 1 taining selecteddosages of ivermectin on freshly ml pentobarbital/2.25 kg. Blood samples were fed. Anophelcs quadrimaculatus Say females. drawn from each dog, centrifuged and the su- Adult survival was the primary factor consid- ered. " Mention of a product doesnot imply a recommen- dation for use or endotsementfor saleby the Univer- l Department of Entomology, Louisiana Agricul- sity of Arkansas or Louisiana State University. a tural Experiment Station, Louisiana State Agricul- Ivermectin and Formulation B were supplied by tural Center, Baton Rouge,LA 70803. Merck, Sharp and Dohme Research Laboratories, 2Division of Laboratory Animal Medicine, School Rahway NJ. 6 of Veterinary Medicine, Louisiana State University, Formulation B is a solvent consisting of 60Vopro- Baton Rouge,LA 70803. pylene glycol and 40% glycerol formal. SEPTEMBER1992 Errncrs oF IvERMECTIN oN Arv. 1vADRTMACULATUI 279 pernatant placed in 3 cc EDTA tubes. Four Table 2. Concentrationsof ivermectin in blood containers, each holding 40 mosquitoes, were sampledprior to and subsequentto Arwpheles taped to each dog with the nylon screening of Etad r i mar ulah-zsfeedin gr the container in contact with 4 previously shorn Concentration areasalong one sideofeach dog (front shoulder, of ivermectin rib cage,hip and inside the hind leg). Mosquitoes (ng/ml)'time were allowedto feedthrough the nylon screening post-treat- Dosage for 30 min. Previous trials had indicated that 30 ment Animal rate min would be sufficient for the mosquitoes to no. fus/ke) 4h 4.5h feed to repletion. After this period, the con- tainers were removed,and the mosquitoes,while 110 39 37 still in the original containers, were provided 2r0 27 26 310 45 37 cotton balls soaked in lIVo sugar water as a Mean dl ild carbohydrate source.Blood sampleswere taken 4 500 191 157 again and handled as before.Blood sampleswere 5 500 161 146 packedin ice and shippedto Merck Laboratories 6 500 205 t75 for ivermectin concentration analysis. Mosqui- Mean 186 159 toes were transported to the University of Ar- 7 1,000 394 363 kansas Medical-Veterinary Entomology Labo- 8 1,000 369 305 ratory in Fayetteville, AR to continue the study. 9 1,000 96 180 Mean Mortality readingswere taken 24 and48 h post- 286 282 10 2,500 629 554 feeding. Data were subjected to analysis ofvar- 11 2,500 601 494 iance and means were separated by Duncan's 12 2,500 r34 101 new multiple-range test (Dowdy and Wearden Mean 456 383 1991). 13 Control 00 A 50-ml aliquot of blood was taken from one 14 Control 00 dog in eachtreatment and control group,packed 15 Control 00 in ice and transported to Fayetteville to feed on ] Initial blood sampleswere taken 4 h after dogs An. quadrimaculatus via a natural lambskin- weretreated. membrane,i.e., condom. Membrane feeding was 2Blood samplesanalyzed by high-pressureliquid initiated to ensure that substanceson the hair chromatography. or skin of the dog had not influenced the out- come of the test. The mosquitoeswere collected at the samelocation near Stuttgart, transported water bath and then placed on the top of the to Fayetteville, and handled in the laboratory as cardboard containers for mosquitoes to feed. previously describedfor those mosquitoesused Four containers,each containing 40 mosquitoes, in the dog-host test. The procedure was begun were used for each treatment. Mosquitoes fed 72h after blood was drawn from the dogs.Con- on the condoms through the nylon screen as domscontaining blood wereheated to 38'C in a discussedpreviously. Mortality was determined at 24 and 48 h, and data were analyzed as previously described. Table1. Percentmortality of Anopheles quadrimaculatusfed on bloodcontaining tte.-ecttn* RESULTS AND DISCUSSION (hours) Posttreatment Mortality rates exceeded90% for mosquitoes Lambskin-mem- fed on dogs at all rates of ivermectin Dogs at 24 h branes post-feeding (Table 1). Mortality in mosquitoes Dosage rates fed on the lambskin-membranes 0'e/ke) 24h 48 h 24h 48h also exceeded 90Voat all rates at 24 h post-feeding,except the 10 90.5Aa 98.6Aa 65.4Bb 90.8Aa l0 pg/kg treatment (65.4%. However at 48 h 500 93.2Aa 99.5Aa 92.6Aa 9Z.3Aa post-feeding, mortality at that particular 1,000 94.4Aa 100.0Aa gg.2Aa 100.0Aa treat- 2,500 96.9Aa 100.0Aa 100.0Aa 100.0Aa ment level increasedto 90.8% and was not sig- Control 1.0Bb 4.3Ab 1.6Bc 3.4Ab nificantly different (P > 0.05) from the other 3 t dosages.The mortality recorded at all dosages Means in the samerow followedby the same upper exceeded90% in both dog-fed case letter are not sigrrificantly different (P > 0.0S and the lambskin- level) by DMRT. membrane-fed groups after 48 h post-feeding. 2 Means in the sarnecolumn followed bv the same The 2 highest dosage rates resulted in 100% lower case letter are not significantly diffirent (p = mortality; whereas,the control mortality never 0.05 level) by DMRT. exceeded,4.37o. 280 JoURNALoF THEAurnrcer Moseurro CorrRor, AssocrnrroN VoL.8,No. 3 We prepared individual oviposition cups for as an anthelminthic has increaseddramatically mosquitoesto measurefecundity as well as mor- in canines and it is likely that ivermectin is tality but the high rate of mortality precluded often imbibed during blood meal acquisitionsby any measurementof fecundity. Resultsfrom this female mosquitoes. Its effect on mosquito fe- study demonstratedmuch higher ivermectin ac- cundity as well as survival is an area requiring tivity against a mosquito speciesthan previously further evaluation. reported. The blood ivermectin concentrationsrecorded ACKNOWLEDGMENTS in the 10 prg/kggroup (Table 2) are much higher than Tesh and Guzman (1990)recorded as caus- We are grateful to Richard Endris of Merck, ing egg infertility in culicine mosquitoes. The Inc. for his assistancein the project and to David blood ivermectin concentrationsat all other dos- Fink, Pierre DeMontigny and JessicaCha of Merck Laboratories for ages exceededthe LDro recorded by Tesh and conducting the blood sample analysis. Guzman (1990) for Ae. aegypti. All concentra- tions producedvery high mortality in An.
Load more

Recommended publications
  • Outcome of Different Therapeutic Interventions in Mild COVID-19 Patients in a Single OPD Clinic of West Bengal: a Retrospective Study
    medRxiv preprint doi: https://doi.org/10.1101/2021.03.08.21252883; this version posted March 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license . Title page Outcome of Different Therapeutic Interventions in Mild COVID-19 Patients in a Single OPD Clinic of West Bengal: A Retrospective study Running Title: Mild COVID-19 and the Buffet of Treatments: A case series Sayak Roy1, Shambo Samrat Samajdar2, Santanu K Tripathi3, Shatavisa Mukherjee4, Kingshuk Bhattacharjee5 1. Consultant Physician, Dept. of Internal Medicine, Medica Superspeciality Hospital, Kolkata; ORCID ID: https://orcid.org/0000-0002-6185-9375 2. Senior Resident, Dept of Clinical & Experimental Pharmacology, School of Tropical Medicine, Kolkata. 3. Dean (Academics) and Head, Dept of Pharmacology, Netaji Subhash Medical College & Hospital, Bihta, Patna 4. PhD Research Scholar, Dept of Clinical & Experimental Pharmacology, School of Tropical Medicine, Kolkata. ORCID ID: https://orcid.org/0000-0001-9524-1525 5. Independent Biostatistician, Kolkata Corresponding Author: Dr. Sayak Roy 609, G.T.Road, Battala, Serampore, Hooghly, WB, India; PIN – 712201 Email: [email protected] Words: 1906 Tables: 2 References: 20 Informed Consent and Institutional ethical clearance: Taken Conflicts of interest: None Funding: None Acknowledgement: None Data availability: Available on request with the corresponding author NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1 medRxiv preprint doi: https://doi.org/10.1101/2021.03.08.21252883; this version posted March 12, 2021.
    [Show full text]
  • Exploring the Activity of an Inhibitory Neurosteroid at GABAA Receptors
    1 Exploring the activity of an inhibitory neurosteroid at GABAA receptors Sandra Seljeset A thesis submitted to University College London for the Degree of Doctor of Philosophy November 2016 Department of Neuroscience, Physiology and Pharmacology University College London Gower Street WC1E 6BT 2 Declaration I, Sandra Seljeset, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I can confirm that this has been indicated in the thesis. 3 Abstract The GABAA receptor is the main mediator of inhibitory neurotransmission in the central nervous system. Its activity is regulated by various endogenous molecules that act either by directly modulating the receptor or by affecting the presynaptic release of GABA. Neurosteroids are an important class of endogenous modulators, and can either potentiate or inhibit GABAA receptor function. Whereas the binding site and physiological roles of the potentiating neurosteroids are well characterised, less is known about the role of inhibitory neurosteroids in modulating GABAA receptors. Using hippocampal cultures and recombinant GABAA receptors expressed in HEK cells, the binding and functional profile of the inhibitory neurosteroid pregnenolone sulphate (PS) were studied using whole-cell patch-clamp recordings. In HEK cells, PS inhibited steady-state GABA currents more than peak currents. Receptor subtype selectivity was minimal, except that the ρ1 receptor was largely insensitive. PS showed state-dependence but little voltage-sensitivity and did not compete with the open-channel blocker picrotoxinin for binding, suggesting that the channel pore is an unlikely binding site. By using ρ1-α1/β2/γ2L receptor chimeras and point mutations, the binding site for PS was probed.
    [Show full text]
  • 268 Part 522—Implantation Or Injectable Dosage Form
    § 520.2645 21 CFR Ch. I (4–1–18 Edition) (ii) Indications for use. For the control 522.82 Aminopropazine. of American foulbrood (Paenibacillus 522.84 Beta-aminopropionitrile. larvae). 522.88 Amoxicillin. 522.90 Ampicillin injectable dosage forms. (iii) Limitations. The drug should be 522.90a Ampicillin trihydrate suspension. fed early in the spring or fall and con- 522.90b Ampicillin trihydrate powder for in- sumed by the bees before the main jection. honey flow begins, to avoid contamina- 522.90c Ampicillin sodium. tion of production honey. Complete 522.144 Arsenamide. treatments at least 4 weeks before 522.147 Atipamezole. main honey flow. 522.150 Azaperone. 522.161 Betamethasone. [40 FR 13838, Mar. 27, 1975, as amended at 50 522.163 Betamethasone dipropionate and FR 49841, Dec. 5, 1985; 59 FR 14365, Mar. 28, betamethasone sodium phosphate aque- 1994; 62 FR 39443, July 23, 1997; 68 FR 24879, ous suspension. May 9, 2003; 70 FR 69439, Nov. 16, 2005; 73 FR 522.167 Betamethasone sodium phosphate 76946, Dec. 18, 2008; 75 FR 76259, Dec. 8, 2010; and betamethasone acetate. 76 FR 59024, Sept. 23, 2011; 77 FR 29217, May 522.204 Boldenone. 17, 2012; 79 FR 37620, July 2, 2014; 79 FR 53136, 522.224 Bupivacaine. Sept. 8, 2014; 79 FR 64116, Oct. 28, 2014; 80 FR 522.230 Buprenorphine. 34278, June 16, 2015; 81 FR 48702, July 26, 2016] 522.234 Butamisole. 522.246 Butorphanol. § 520.2645 Tylvalosin. 522.275 N-Butylscopolammonium. 522.300 Carfentanil. (a) Specifications. Granules containing 522.304 Carprofen. 62.5 percent tylvalosin (w/w) as 522.311 Cefovecin.
    [Show full text]
  • A Pilot Study of the Safety and Initial Efficacy of Ivermectin for The
    ALCOHOLISM:CLINICAL AND EXPERIMENTAL RESEARCH Vol. 40, No. 6 June 2016 A Pilot Study of the Safety and Initial Efficacy of Ivermectin for the Treatment of Alcohol Use Disorder Daniel J. O. Roche, Megan M. Yardley, Katy F. Lunny, Stan G. Louie, Daryl L. Davies, Karen Miotto, and Lara A. Ray Background: Ivermectin (IVM) is an antiparasitic agent that has been shown to reduce alcohol intake in mice, suggesting IVM as a potential treatment for alcohol use disorder (AUD). However, the safety profile of IVM administered in combination with an intoxicating dose of alcohol has not been characterized in humans. Methods: This pilot project sought to provide the first clinical evidence that IVM could be reposi- tioned as an AUD pharmacotherapy by examining (i) the safety of combining IVM (30 mg oral , once a day [QD]) with an intoxicating dose of intravenous alcohol (0.08 g/dl) and (ii) the effects of IVM on alcohol cue-induced craving and subjective response to alcohol. Eleven individuals with AUD partici- pated in a randomized, placebo-controlled, crossover study in which they received the study medica- tion, participated in a cue exposure paradigm followed by intravenous alcohol administration, and remained in an inpatient unit overnight for observation. Results: IVM treatment, versus placebo, did not increase the number or severity of adverse effects during alcohol administration or throughout the visit. However, IVM did not reduce cue-induced crav- ing nor did it significantly affect subjective response to alcohol. Conclusions: These results suggest that IVM (30 mg oral, QD) is safe in combination with an intoxi- cating dose of alcohol, but do not provide evidence that this dose of IVM is effective in reducing alcohol craving or its reinforcing effects.
    [Show full text]
  • Ivermectin and Human Immunity Protocol ID
    Cover Sheet Clinicaltrials.gov ID NCT03459794 Protocol Ivermectin and human immunity ID#STUDY00005069 Adrian Adrian PI: Primary Contact: Wolstenholme Wolstenholme Submission Initial Study Type: IRB Brooke Harwell Parent Protocol: Coordinator: Review Category: Approved 9/27/2017 Date: Expiration 7/11/2018 Date: Print: STUDY00005069 - Ivermectin and human immunity https://ovpr-click-prod.ovpr.uga.edu/uga-ovpr/ResourceAdministration/P... Date: Monday, November 26, 2018 12:06:50 PM View: SF: Basic Information UGA v2 Section 1 - Basic Information 1. * Title of Study: If the study is/will be funded, the IRB recommends The effects of ivermectin on the normal human matching the title in the funding proposal. immune system 2. * Short Title: This can match the long title or be shortened if your Ivermectin and human immunity project uses an acronym or nickname; however, all system generated lists, searches, and documents (including approval letters) will show the short title. 3. Only UGA faculty and selected staff members (senior Principal Investigator (faculty or senior staff) are eligible to serve as PI. See the policy for staff only - see help): more information: http://research.uga.edu/documents Adrian Wolstenholme /eligibility 4. * Does the Principal Investigator have a See the policy for more information: https://research.uga.edu/docs/policies financial interest related to this /compliance research? Yes No /hso/PP_Financial%20Conflicts%20of%20Interests.pdf 5. If you are not sure if your project needs IRB * Are you requesting determination if review, choose "Yes" in the first question. A form will your project meets the definition of open and provide prompts to guide you through an initial assessment to see if your project needs IRB Yes No human subjects research? review.
    [Show full text]
  • During Prepartum Period on Mastitis and Postpartum Reproductive Efciency Measurements in Egyptian Baladi Cows
    Impact of treatment with anti-parasitic (Ivermectin) during prepartum period on mastitis and postpartum reproductive eciency measurements in Egyptian Baladi cows Ahmed Ismail Damarany ( [email protected] ) Aswan University Faculty of Agriculture and Natural Resources https://orcid.org/0000-0002-0757-933X Research Article Keywords: Ivermectin, mastitis, postpartum reproductive eciency measurements, Baladi cows Posted Date: August 23rd, 2021 DOI: https://doi.org/10.21203/rs.3.rs-823328/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/19 Abstract The current investigation was designed to determine the effect of treatment with anti-parasites (Ivermectin) on mastitis and postpartum reproductive eciency measurements in Egyptian Baladi cows. Twenty-four of the cows included in this study were split into two groups. The rst group (n = 12 cows) was injected two months prepartum with two doses (15 days inter-treatment) of IVOMEC® Plus solution subcutaneously behind the shoulder, 1ml/50kg live body weight as prescribed by the manufacturer, whilst the other group (n = 12 cows) was used as a control group. The present results revealed that the incident rate of mastitis in treated cows’ group was signicantly (P < 0.05) lower (16.7%) than control cows’ group (41.7%). The conception rate in treated cows’ group was signicantly (P < 0.05) higher (66.7%) compared with (33.3%) in control group. The time from calving to conception in treated cows was signicantly (P < 0.05) lower 86.5 ± 11.4 days compared to 123.3 ± 13.2 days in the control group.
    [Show full text]
  • Crystal Polymorphism and Pseudopolymorphism of Ivermectin
    Crystal polymorphism and pseudopolymorphism of ivermectin Michiel Lucas Josias Grobler B.Pharm. Dissertation submitted in partial fulfilment of the requirements for the degree Magister Scientiae in the Department of Pharmaceutics at the Potchefstroomse Universiteit vir Christelike Hoer Onderwys. Supervisor: Prof. M.M. de Villiers. Co-superviso·rs: Dr. W. Liebenberg. Mr. A.F. Marais. POTCHEFSTROOM 2000 TABLE OF CONTENTS TABLE OF CONTENTS ABSTRACT vii UITTREKSEL ix AIM AND OBJECTIVES xi CHAPTER 1: Veterinary formulation: the influence of animal and environmental factors and the solid state properties of drugs 1.1 Introduction 1 1.2 Veterinary dosage forms 2 1.3 Animal and environmental factors influencing veterinary formulation 3 design 1.3.1 Geographical location 3 1.3.2 Dietary habit 4 1.3.3 Gastrointestinal tract 4 1.3.4 Metabolism 5 1.3.5 Renal excretion 6 1.3.6 Biliary excretion 6 1.3. 7 Skin type 7 1 .3.8 Endocrinology 7 1.3.9 Animal behaviour 7 1.3.10 Drug distribution 7 1.3.11 Age 8 1.3.12 Disease states 9 1.3.13 Residues 9 1.3.14 Single or herd dosing 9 1.3.15 Wild or tame 10 1.3.16 Stability 11 1.4 Solid state properties of drugs that influence veterinary formulation 11 design 1.4.1 Effect of particle size on veterinary drug formulations 12 1.4.1.1 Effect of particle size on dissolution and solubility 12 1.4.1.2 Effect of particle size on suspension stability 13 1.4.1.3 Effect of particle size reduction on drug stability 14 1.4.1.4 Effect of particle size on administration of drugs in feed 14 1.4.2 The effect of crystal forms
    [Show full text]
  • Interactions with Protease Inhibitors Charts Revised February 2018
    www.hiv-druginteractions.org Interactions with Protease Inhibitors Charts revised February 2018. Full information available at www.hiv-druginteractions.org Page 1 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. ATV Cobi DRV FPV IDV LPV RTV SQV TPV ATV Cobi DRV FPV IDV LPV RTV SQV TPV Anaesthetics & Muscle Relaxants Antibacterials (continued) Alcuronium Ertapenem Bupivacaine Erythromycin Cisatracurium Ethambutol Desflurane Ethionamide Dexmedetomidine Flucloxacillin Enflurane Gentamicin Ephedrine Imipenem/Cilastatin Halothane Isoniazid Isoflurane Kanamycin Ketamine Levofloxacin Linezolid Nitrous oxide Meropenem Propofol Metronidazole Rocuronium Moxifloxacin Sevoflurane Nitrofurantoin Sufentanil Ofloxacin Suxamethonium (succinylcholine) Para-aminosalicylic acid Tetracaine Penicillins Thiopental for distribution. for Pyrazinamide Tizanidine Rifabutin Vecuronium Rifampicin Analgesics Rifapentine Alfentanil Rifaximin Aspirin Spectinomycin Buprenorphine Streptomycin Celecoxib Sulfadiazine Codeine Telithromycin Tetracyclines
    [Show full text]
  • Calcium-Engaged Mechanisms of Nongenomic Action of Neurosteroids
    Calcium-engaged Mechanisms of Nongenomic Action of Neurosteroids The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Rebas, Elzbieta, Tomasz Radzik, Tomasz Boczek, and Ludmila Zylinska. 2017. “Calcium-engaged Mechanisms of Nongenomic Action of Neurosteroids.” Current Neuropharmacology 15 (8): 1174-1191. doi:10.2174/1570159X15666170329091935. http:// dx.doi.org/10.2174/1570159X15666170329091935. Published Version doi:10.2174/1570159X15666170329091935 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:37160234 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA 1174 Send Orders for Reprints to [email protected] Current Neuropharmacology, 2017, 15, 1174-1191 REVIEW ARTICLE ISSN: 1570-159X eISSN: 1875-6190 Impact Factor: 3.365 Calcium-engaged Mechanisms of Nongenomic Action of Neurosteroids BENTHAM SCIENCE Elzbieta Rebas1, Tomasz Radzik1, Tomasz Boczek1,2 and Ludmila Zylinska1,* 1Department of Molecular Neurochemistry, Faculty of Health Sciences, Medical University of Lodz, Poland; 2Boston Children’s Hospital and Harvard Medical School, Boston, USA Abstract: Background: Neurosteroids form the unique group because of their dual mechanism of action. Classically, they bind to specific intracellular and/or nuclear receptors, and next modify genes transcription. Another mode of action is linked with the rapid effects induced at the plasma membrane level within seconds or milliseconds. The key molecules in neurotransmission are calcium ions, thereby we focus on the recent advances in understanding of complex signaling crosstalk between action of neurosteroids and calcium-engaged events.
    [Show full text]
  • Naturopathic Physicians Regulation
    PROPOSED AMENDMENTS – NATUROPATHIC PHYSICIANS REGULATION Health Professions Act NATUROPATHIC PHYSICIANS REGULATION PROPOSED TO REPLACE B.C. REG. 282/2008 Contents 1 Definitions 2 College name 3 Reserved titles 4 Scope of practice 5 Restricted activities 6 Limits or conditions on services and restricted activities 7 Patient relations program 8 Health profession corporations 1 PROPOSED AMENDMENTS – NATUROPATHIC PHYSICIANS REGULATION Definitions 1 In this regulation: "Act" means the Health Professions Act; "compound" means (a) in respect of a drug, to mix with one or more other ingredients, and (b) in respect of a therapeutic diet, to mix two or more ingredients; "dispense" has the same meaning as in the Pharmacy Operations and Drug Scheduling Act, but excludes a sale, as defined in that Act; "drug" means, except in the definition of "substance", a drug (a) specified in Schedule I of the Drug Schedules Regulation, B.C. Reg. 9/98, other than a drug set out in the Schedule of this regulation, or (b) specified in Schedule II of the Drug Schedules Regulation; "enteral instillation" means instillation directly into the gastrointestinal tract; "minor surgery" means a surgical procedure that (a) is performed, for a diagnostic or therapeutic purpose, on a superficial anatomical structure, and (b) does not involve (i) sedation, general anaesthesia or respiratory assistance, or (ii) a material risk to life; "naturopathic medicine" means the health profession in which a person provides the services of prevention, assessment and treatment of an individual's
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • Central and Peripheral Neurotoxic Effects of Ivermectin in Rats
    FULL PAPER Toxicology Central and Peripheral Neurotoxic Effects of Ivermectin in Rats Saša M TRAILOVIĆ1) and Jelena Trailović NEDELJKOVIĆ2) 1)Faculty of Veterinary Medicine, Department of Pharmacology and Toxicology, University of Belgrade, Bulevar oslobodjenja 18, Belgrade 11000 and 2)Faculty of Veterinary Medicine, Department of Nutrition, University of Belgrade, Bulevar oslobodjenja 18, Belgrade 11000, Serbia (Received 27 September 2010/Accepted 6 December 2010/Published online in J-STAGE 20 December 2010) ABSTRACT. Ivermectin is considered a very safe drug; however, there are reports of toxic effects in particularly sensitive populations or due to accidental overdose. The aim of this study was (1) to further characterize the central and peripheral toxic effects of ivermectin in animals and (2) to determine possible therapeutic strategies for use in cases of ivermectin poisoning. We tested the effects of exper- imental doses of ivermectin previously reported to cause various intensities of CNS depression. However, in our study, ivermectin at 2.5, 5.0 and 7.5 mg/kg i.v. did not produce visible CNS depression in rats and 10 mg/kg resulted in sleepiness and staggering 10 to 40 min after application, while a dose of 15 mg/kg caused CNS depression very similar to general anesthesia. Ivermectin dose-dependently potentiates thiopentone-induced sleeping time in rats. Flumazenil (0.2 mg/kg), the benzodiazepine antagonist, did not affect the action of thiopentone; however, it significantly reduced sleeping time in rats treated with a combination of ivermectin (10 mg/kg) and thiopen- tone (25 mg/kg; from 189.86 45.28 min to 83.13 32.22 min; mean SD).
    [Show full text]